Compare

Stevanato Group/$STVN

1D1W1M3M6MYTD1Y5YMAX

About Stevanato Group

Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
Ticker
$STVN
Sector
Health
Primary listing
NYSE
Employees
6,010
Headquarters
Piombino Dese, Italy

Stevanato Group Metrics

BasicAdvanced
$4.2B
27.47
$0.56
0.80
$0.06
0.40%

What the Analysts think about Stevanato Group

Analyst ratings (Buy, Hold, Sell) for Stevanato Group stock.
Analyst projections of the future price of Stevanato Group stock.

Bulls say / Bears say

Third-quarter revenue rose 8% and diluted earnings per share grew 15%, showing that Stevanato continued to grow sales and earnings. Its 2026 outlook also points to adjusted EBITDA of €335.0m–€345.2m. (Business Wire)
High-value solutions grew 16% in the second quarter and made up 45% of revenue, supporting a shift towards more specialised products. This mix helped lift the adjusted EBITDA margin to 26.0%. (Stevanato Group)
A customer won European regulatory approval for a therapy using Stevanato’s proprietary Alina pen injector and cartridge technology. This is evidence that its integrated drug-delivery products are reaching commercial use. (Stevanato Group)
Management expects lower GLP-1 syringe volumes from one customer to slow growth to low single digits in 2027. It says it has backfilled much, but not all, of the affected demand, leaving a near-term growth gap. (Investing.com)
Engineering revenue fell 12% in the third quarter, as weaker visual-inspection and assembly sales outweighed growth in after-sales services. The segment also faces uneven order conversion and project timing, making recovery less predictable. (Business Wire, Investing.com)
The expansion programme still requires substantial spending: third-quarter capital expenditure was €44.8m, and net debt stood at €353.7m at quarter-end. If new capacity takes longer to fill, those investments could weigh on cash generation and returns. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.

Stevanato Group Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Stevanato Group Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing Stevanato Group

Funds
Fund name
Fund size
$STVN weighting
Invesco Dow Jones Islamic Global Developed Markets$IGDA
$1.1B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.